We are live on ! Find out more
MRTX

Mirati Therapeutics, Inc. Common Stock
MRTX

Delisted

MRTX was delisted on the 22nd of January, 2024.

Back to rankings

64 hedge funds and large institutions have $84M invested in Mirati Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

86% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 14

49% more capital invested

Capital invested by funds: $56.5M → $84M (+$27.6M)

3% more funds holding

Funds holding: 62 → 64 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

59% less call options, than puts

Call options by funds: $48K | Put options by funds: $116K

Holders
64
Holders Change
+2
Holders Change %
+3.23%
% of All Funds
1.59%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
26
Reduced
14
Closed
7
Calls
$48K
Puts
$116K
Net Calls
-$68K
Net Calls Change
+$15K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$6.93M
2
AH
Aviva Holdings
Bahamas
+$4.88M
3
BlackRock
BlackRock
New York
+$4.83M
4
ACA
Avoro Capital Advisors
New York
+$4.8M
5
HIM
Hillhouse Investment Management
Cayman Islands
+$3.97M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$4.13M
2
RI
RTW Investments
New York
-$616K
3
SFM
Sphera Funds Management
Israel
-$383K
4
Millennium Management
Millennium Management
New York
-$239K
5
AQR Capital Management
AQR Capital Management
Connecticut
-$169K
Name Holding Trade Value Shares
Change 		Change in
Stake
AH
1
Aviva Holdings
Bahamas
$15M +$4.88M +889,617 +45%
ACA
2
Avoro Capital Advisors
New York
$12.4M +$4.8M +875,000 +58%
BBA
3
Baker Bros. Advisors
New York
$11.8M – – –
BC
4
Broadfin Capital
New York
$10.9M +$6.93M +1,264,800 +153%
BC
5
Boxer Capital
California
$5.4M +$1.53M +280,059 +37%
BlackRock
6
BlackRock
New York
$4.61M +$4.83M +881,699 +22,613%
HIM
7
Hillhouse Investment Management
Cayman Islands
$3.77M +$3.97M +725,000 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$3.56M +$884K +161,303 +31%
Franklin Resources
9
Franklin Resources
California
$1.96M – – –
Alyeska Investment Group
10
Alyeska Investment Group
Illinois
$1.31M +$1.38M +251,988 New
SM
11
Sabby Management
Florida
$1.3M +$822K +150,000 +150%
State Street
12
State Street
Massachusetts
$1.11M +$123K +22,359 +12%
GTC
13
Ghost Tree Capital
New York
$895K – – –
Northern Trust
14
Northern Trust
Illinois
$894K +$166K +30,369 +21%
Renaissance Technologies
15
Renaissance Technologies
New York
$854K +$900K +164,302 New
RA
16
Royce & Associates
New York
$692K +$729K +133,037 New
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$677K +$713K +130,186 New
Geode Capital Management
18
Geode Capital Management
Massachusetts
$618K +$53.3K +9,726 +9%
Millennium Management
19
Millennium Management
New York
$612K -$239K -43,641 -27%
PAM
20
Panagora Asset Management
Massachusetts
$542K +$197K +35,868 +53%
OA
21
Omega Advisors
New York
$520K +$548K +100,000 New
Macquarie Group
22
Macquarie Group
Australia
$416K – – –
CG
23
Cutler Group
California
$354K +$339K +61,873 +976%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$328K +$64.4K +11,753 +23%
Morgan Stanley
25
Morgan Stanley
New York
$276K -$88.2K -16,101 -23%
1
2 3

MRTX Hedge Fund Activity: Q1 2017 in Review

64 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q1 2017, worth a combined $84M — up 49% from $56.5M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new MRTX positions and 7 closed out — a net gain of 6 holders — while 26 added to existing stakes and 14 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $6.93M. The largest seller was Great Point Partners, exiting entirely with an estimated $4.13M sold.

  • 64 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q1 2017, up from 62 in Q4 2016.
  • Funds reported $84M of Mirati Therapeutics, Inc. Common Stock stock for Q1 2017, up 49% quarter-over-quarter.
  • 13 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q1 2017 and 7 closed out, a net change of +6 holders.
  • The largest Mirati Therapeutics, Inc. Common Stock buyer in Q1 2017 was Broadfin Capital, an estimated $6.93M added.
  • The largest Mirati Therapeutics, Inc. Common Stock seller in Q1 2017 was Great Point Partners, an estimated $4.13M sold.

Based on aggregated 13F filings for Q1 2017.